Published in J Exp Med on December 01, 1972
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Platelet-activating factor: receptors and signal transduction. Biochem J (1993) 2.12
Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med (1987) 1.95
Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med (1975) 1.91
Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. J Cell Biol (1992) 1.76
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am J Pathol (1981) 1.56
Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. Br J Pharmacol (1983) 1.53
Sperm preparation for ART. Reprod Biol Endocrinol (2003) 1.52
Activation and desensitization of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. I. Characteristics of the secretory response. J Exp Med (1976) 1.48
Formation of slow-reacting substance of anaphylaxis in human lung tissue and cells before release. J Exp Med (1974) 1.44
Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. J Clin Invest (1982) 1.43
The influence of phagocyte function on glomerular localization of aggregated IgM in rats. Clin Exp Immunol (1978) 1.38
Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Actions (1981) 1.36
Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice. The potential role of intravascular platelet aggregation in its genesis. Am J Pathol (1984) 1.26
Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. Proc Natl Acad Sci U S A (1983) 1.25
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology (1983) 1.24
Increased serum immunoglobulin E concentrations in venereal diseases. Br J Vener Dis (1976) 1.21
Activation of rabbit platelets by platelet-activating factor derived from IgE-sensitized basophils. Characteristics of the aggregation and its dissociation from secretion. J Clin Invest (1977) 1.20
Vascular permeability changes in the central nervous system of rats with hyperacute experimental allergic encephalomyelitis induced with the aid of a substance from Bordetella pertussis. Infect Immun (1978) 1.16
Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol (1990) 1.14
Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci U S A (1980) 1.11
Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes. Infect Immun (1978) 1.11
Isolation of human eosinophil phospholipase D. J Clin Invest (1976) 1.11
Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. Biochem J (1983) 1.10
Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut (1992) 1.10
Evidence for the involvement of IgE-basophil system in acute serum sickness. Clin Exp Immunol (1976) 1.10
Pharmacological approach to acute pancreatitis. World J Gastroenterol (2008) 1.08
Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A (2009) 1.08
The immunological generation of a platelet-activating factor and a platet-lytic factor in the rat. Immunology (1979) 1.07
Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. Am J Pathol (1983) 1.07
The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol (1983) 1.07
Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. J Exp Med (1988) 1.07
Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol (1989) 1.06
Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest (1984) 1.06
Biochemical studies on cell fusion. I. Lipid composition of fusion-resistant cells. J Cell Biol (1985) 1.04
Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol (1984) 1.04
The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol (1980) 1.03
Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest (1994) 1.03
Role of platelet-activating factor in the pathogenesis of acute pancreatitis. World J Gastroenterol (2006) 1.02
Orphan enzymes in ether lipid metabolism. Biochimie (2012) 1.01
Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. J Immunol (2010) 1.01
Mechanisms of exocytosis in phagocytic inflammatory cells. Parke-Davis Award Lecture. Am J Pathol (1980) 1.00
Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol (1990) 0.98
Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion. PLoS Pathog (2012) 0.98
The binding of rabbit basophil-derived platelet-activating factor to rabbit platelets. Am J Pathol (1980) 0.95
1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity. Br J Pharmacol (1991) 0.94
The interaction of anti-glomerular basement membrane antibody deposition with immune elimination of bovine serum albumin in the rabbit. Clin Exp Immunol (1979) 0.94
Platelet-activating factor acetylhydrolase activity in maternal, fetal, and newborn rabbit plasma during pregnancy and lactation. Proc Natl Acad Sci U S A (1988) 0.94
Traumatic brain injury-associated coagulopathy. J Neurotrauma (2012) 0.93
Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. Am J Pathol (1983) 0.93
Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob Agents Chemother (1992) 0.92
Biochemical studies on cell fusion. II. Control of fusion response by lipid alteration. J Cell Biol (1985) 0.92
Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron (2008) 0.92
Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. Biochem J (1984) 0.92
Modulatory role of cyclic AMP in the release of platelet-activating factor from human polymorphonuclear leucocytes. Immunology (1982) 0.90
The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). Biochem J (1984) 0.89
Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. Agents Actions (1986) 0.88
In vitro histamine and serotonin release by radiographic contrast media (RCM). Complement-dependent and -independent release reaction and changes in ultrastructure of human blood cells. Clin Exp Immunol (1978) 0.88
Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. Agents Actions (1981) 0.87
Absence of an anaphylactic vasopermeability mechanism for immune complex deposition in the Heymann nephritis of rats. Clin Exp Immunol (1980) 0.87
Activation of stimulus-specific serine esterases (proteases) in the initiation of platelet secretion. I. Demonstration with organophosphorus inhibitors. J Exp Med (1976) 0.87
Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). Am J Pathol (1983) 0.87
Platelet activating factor: release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion. Gut (1996) 0.86
Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: implications for the biologically active form of PAF. Br J Pharmacol (1992) 0.86
Up-regulation of platelet-activating factor synthases and its receptor in spinal cord contribute to development of neuropathic pain following peripheral nerve injury. Mol Pain (2012) 0.85
Evidence of an immediate hypersensitivity mechanism in systemic lupus erythematosus. Ann Rheum Dis (1980) 0.85
Pulmonary platelet kinetics in asthma. Thorax (1985) 0.85
Platelet activating factor: an inhibitor of neutrophil activation? Clin Exp Immunol (1981) 0.85
Pharmacological modulation of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. Immunology (1980) 0.85
Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation. Br J Clin Pharmacol (1987) 0.85
Platelet-activating factor-induced hydrolysis of phosphatidylinositol 4,5-bisphosphate stimulates the production of reactive oxygen intermediates in macrophages. Biochem J (1988) 0.85
Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Thorax (1997) 0.85
Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs. Basic Res Cardiol (1987) 0.84
Biosynthesis of platelet-activating factor by cultured rat Kupffer cells stimulated with calcium ionophore A23187. Biochem J (1989) 0.84
Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. Immunology (1984) 0.84
Release of a slow-reacting substance from rabbit platelets. J Clin Invest (1981) 0.84
Opposing effects of platelet-activating factor and lyso-platelet-activating factor on neutrophil and platelet activation. Mol Pharmacol (2008) 0.84
Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung. Br J Pharmacol (1991) 0.84
Characterization of streptococcal platelet-activating factor acetylhydrolase variants that are involved in innate immune evasion. Infect Immun (2013) 0.84
Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis. J Allergy Clin Immunol (2016) 0.84
Polymorphonuclear leucocytes release a factor(s) that induces platelet aggregation and ATP release after interaction with insoluble and surface-fixed immune complexes. Clin Exp Immunol (1982) 0.84
The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. Agents Actions (1984) 0.83
Byssinosis: Release of prostaglandins, thromboxane, and 5-hydroxytryptamine in bronchopulmonary lavage fluid after inhalation of cotton dust extracts. Am J Pathol (1985) 0.83
Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. Immunology (1983) 0.83
Platelets and Their Interactions with Other Immune Cells. Compr Physiol (2015) 0.83
Platelet-leukocyte interaction: activation of rabbit platelets by FMLP-stimulated neutrophils. Br J Pharmacol (1987) 0.82
Non-platelet-mediated vascular actions of 1-O-alkyl-2-acetyl-sn-3-glyceryl phosphorycholine (a synthetic PAF). Agents Actions (1981) 0.82
Activation of human platelets by platelet activating factor (PAF) derived from sensitized rabbit basophils. Immunology (1978) 0.82
Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells. Cell Death Dis (2015) 0.82
Role of autocrine mediators in the regulation of embryo viability: lessons from animal models. J Assist Reprod Genet (1998) 0.81
Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin. Gut (1993) 0.81
Platelet-activating factor (PAF) as a mediator of neutrophil-platelet interactions in inflammation. Agents Actions (1981) 0.81
The role of histamine in the acute inflammatory responses to intradermal platelet activating factor. Br J Clin Pharmacol (1991) 0.81
Is platelet-activating factor (PAF-acether) synthesis by murine peritoneal cells (PC) a two-step process? Agents Actions (1981) 0.81
Downregulation of angiogenesis factors, VEGF and PDGF, after rapid IgE desensitization and oral immunotherapy in children with food allergy. Biomed Res Int (2014) 0.81
The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem (1966) 46.81
Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction. Prog Allergy (1958) 14.20
Studies on inflammation. 1. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol (1961) 11.52
PLATELET SEQUESTRATION IN MAN. I. METHODS. J Clin Invest (1964) 6.10
The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces. J Exp Med (1968) 4.29
Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state. J Lab Clin Med (1962) 4.25
STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. I. STRUCTURAL STUDIES. J Exp Med (1963) 3.83
Studies on circulating immune complexes. 3. Factors governing the ability of circulating complexes to localize in blood vessels. J Exp Med (1968) 3.80
Localization of colloidal substances in vascular endothelium: a mechanism of tissue damage. I. Factors causing the pathologic deposition of colloidal carbon. Am J Pathol (1959) 3.28
Acute immune complex disease in rabbits. The role of complement and of a leukocyte-dependent release of vasoactive amines from platelets. J Exp Med (1971) 2.92
Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol (1970) 2.91
The passage of colloidal particles across the dermal capillary wall under the influence of histamine. Q J Exp Physiol Cogn Med Sci (1959) 2.47
Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement. J Exp Med (1969) 2.30
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J Exp Med (1970) 2.22
Rabbit anaphylactic antibody. J Exp Med (1966) 2.01
Colorimetric investigation of the uptake of an intravenously injected protein (horseradish peroxidase) by rat kidney and effects of competition by egg white. J Cell Biol (1962) 1.96
STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. II. PATHOGENETIC AND PHARMACODYNAMIC STUDIES. J Exp Med (1963) 1.92
Antigen induced histamine release from platelets of rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med (1966) 1.51
Destruction of rabbit platelets in the allergic response of sensitized leukocytes. I. Demonstration of a fluid phase intermediate. J Immunol (1971) 1.48
In vitro histamine release from blood cellular elements of rabbits infected with Schistosoma mansoni. Proc Soc Exp Biol Med (1968) 1.44
Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement. II. Interaction of platelets with neutrophils. J Immunol (1970) 1.38
Mechanisms of reaginic hypersensitivity: a review. Clin Allergy (1971) 1.35
The relationships between serum complement activity and the development of allergic lesions in rabbits. J Exp Med (1961) 1.29
Rabbit homocytotropic antibody. A unique rabbit immunoglobulin analogous to human IgE. J Exp Med (1969) 1.26
The nature of the reaction of antigen with lymphocytes from rabbits infected with Schistosoma mansoni on the release of histamine from rabbit platelets. J Immunol (1970) 1.07
Destruction of rabbit platelets in the allergic response of sensitized leukocytes. II. Evidence for basophil involvement. J Immunol (1971) 0.98
Interaction of rabbit platelets and leukocytes in the release of histamine. Electron microscopic observations. Am J Pathol (1971) 0.92
In vivo passive sensitization of normal rabbit leukocytes with sera demonstrating homocytotropic antibody activity. Int Arch Allergy Appl Immunol (1971) 0.90
Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest (1998) 13.05
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol (1992) 11.24
Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest (1989) 7.60
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol (1969) 6.97
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature (2000) 6.12
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J Immunol (1971) 5.76
Immune complex disease in experimental animals and man. Adv Immunol (1973) 5.30
Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol (1985) 5.02
C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med (2001) 4.54
The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces. J Exp Med (1968) 4.29
The adherence of leucocytes and platelets induced by fixed IgG antibody or complement. Immunology (1969) 3.99
Immunologic tissue injury mediated by neutrophilic leukocytes. Adv Immunol (1968) 3.82
Studies on circulating immune complexes. 3. Factors governing the ability of circulating complexes to localize in blood vessels. J Exp Med (1968) 3.80
Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol (1992) 3.79
Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med (1984) 3.79
A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 3.65
Polymorphonuclear leukocytes in immunologic reactions. The destruction of vascular basement membrane in vivo and in vitro. J Exp Med (1966) 3.57
The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ (1998) 3.23
Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages. J Exp Med (1982) 3.22
Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose. J Clin Invest (1975) 3.17
Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol (2001) 3.17
Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med (1973) 3.15
Killing of Listeria monocytogenes by inflammatory neutrophils and mononuclear phagocytes from immune and nonimmune mice. J Leukoc Biol (1984) 3.02
Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest (2001) 2.96
Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest (1987) 2.93
Acute immune complex disease in rabbits. The role of complement and of a leukocyte-dependent release of vasoactive amines from platelets. J Exp Med (1971) 2.92
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
Interaction of cells with immune complexes: adherence, release of constituents, and tissue injury. J Exp Med (1971) 2.88
The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J Immunol (1971) 2.85
Intracellular control of human neutrophil secretion. I. C5a-induced stimulus-specific desensitization and the effects of cytochalasin B. J Immunol (1978) 2.82
The release of granule enzymes from human neutrophils stimulated by aggregated immunoglobulins of different classes and subclasses. J Immunol (1972) 2.80
Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem (2001) 2.74
Pathologic mechanisms in neutrophil-mediated injury. Am J Pathol (1972) 2.57
[Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine]. C R Seances Acad Sci D (1979) 2.53
Clearance of apoptotic cells by phagocytes. Cell Death Differ (2007) 2.53
Development of functional complement receptors during in vitro maturation of human monocytes into macrophages. J Immunol (1980) 2.47
Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells. J Immunol (1999) 2.43
Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest (1987) 2.40
Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest (1983) 2.37
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function. Immunopharmacology (1980) 2.35
In vitro studies of immunologically induced secretion of mediators from cells and related phenomena. Adv Immunol (1973) 2.32
Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement. J Exp Med (1969) 2.30
Glomerular basement membrane damage in immunological glomerulonephritis. Immunology (1968) 2.29
Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro. J Clin Invest (1984) 2.27
Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest (1986) 2.22
Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J Exp Med (1970) 2.22
Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol (2001) 2.22
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol (1979) 2.10
The sequential release of granule constitutents from human neutrophils. J Immunol (1980) 2.09
Structural analysis of purified platelet-activating factor by lipases. Nature (1977) 2.09
Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest (1986) 2.08
Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells. J Exp Med (1978) 2.03
CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3). J Immunol (1998) 2.03
Mechanisms of oxidant-mediated cell injury. The glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem (1988) 2.03
The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol (1979) 2.02
Isolation and characterization of permeability factors from rabbit neutrophils. J Exp Med (1968) 2.00
Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature (1974) 1.97
Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest (1987) 1.96
Phagocytosis of aged human neutrophils by macrophages is mediated by a novel "charge-sensitive" recognition mechanism. J Clin Invest (1989) 1.93
Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med (1975) 1.91
Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A (1986) 1.87
Mediators of the arthus and related reactions. Prog Allergy (1967) 1.85
Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monocytes and monocyte-derived macrophages. J Reticuloendothel Soc (1980) 1.85
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A (1990) 1.84
Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest (1983) 1.83
Human neutrophil-derived platelet activating factor. J Immunol (1980) 1.82
Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J Clin Invest (1993) 1.82
Fate of Listeria monocytogenes in resident and activated macrophages. Infect Immun (1981) 1.82
Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest (1987) 1.80
Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol (2000) 1.76
Intravascular aggregation and pulmonary sequestration of platelets during IgE-induced systemic anaphylaxis in the rabbit: abrogation of lethal anaphylactic shock by platelet depletion. J Immunol (1977) 1.76
Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest (1979) 1.74
Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med (1974) 1.74
Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils. Lab Invest (1988) 1.72
Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest (1989) 1.70
Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol (1979) 1.69
Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest (1982) 1.68
Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem (1997) 1.67
The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor). J Exp Med (1971) 1.65
Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. J Clin Invest (1973) 1.64
Enhanced accumulation of inflammatory neutrophils and macrophages mediated by transfer of T cells from mice immunized with Listeria monocytogenes. J Immunol (1985) 1.64
Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol (1993) 1.63
Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp Med (1972) 1.62
Controlled clinical trial of homoeopathy in postoperative ileus. Lancet (1988) 1.61
Enhancement of immunologically induced granule exocytosis from neutrophils by cytochalasin B. J Immunol (1973) 1.60
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A (1976) 1.59
Nonimmunological production of leukotrienes induced by platelet-activating factor. Science (1982) 1.58
In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood (1984) 1.58
Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med (1981) 1.57